PT - JOURNAL ARTICLE AU - Maier, Hannah E. AU - Balmaseda, Angel AU - Ojeda, Sergio AU - Cerpas, Cristiam AU - Sanchez, Nery AU - Plazaola, Miguel AU - van Bakel, Harm AU - Kubale, John AU - Lopez, Roger AU - Saborio, Saira AU - Barilla, Carlos AU - , AU - Harris, Eva AU - Kuan, Guillermina AU - Gordon, Aubree TI - An immune correlate of SARS-CoV-2 infection and severity of reinfections AID - 10.1101/2021.11.23.21266767 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.23.21266767 4099 - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266767.short 4100 - http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266767.full AB - Background An immune correlate of protection from SARS-CoV-2 infection is urgently needed.Methods We used an ongoing household cohort with an embedded transmission study that closely monitors participants regardless of symptom status. Real-time reverse-transcription polymerase chain reaction (RT-PCR) and Enzyme-linked immunosorbent assays (ELISAs) were used to measure infections and seropositivity. Sequencing was performed to determine circulating strains of SARS-CoV-2. We investigated the protection associated with seropositivity resulting from prior infection, the anti-spike antibody titers needed for protection, and we compared the severity of first and second infections.Results In March 2021, 62.3% of the cohort was seropositive. After March 2021, gamma and delta variants predominated. Seropositivity was associated with 69.2% protection from any infection (95% CI: 60.7%-75.9%), with higher protection against moderate or severe infection (79.4%, 95% CI: 64.9%-87.9%). Anti-spike titers of 327 and 2,551 were associated with 50% and 80% protection from any infection; titers of 284 and 656 were sufficient for protection against moderate or severe disease. Second infections were less severe than first infections (Relative Risk (RR) of moderated or severe disease: 0.6, 95% CI: 0.38-0.98; RR of subclinical disease:1.9, 95% CI: 1.33-2.73).Conclusions Prior infection-induced immunity is protective against infection when predominantly gamma and delta SARS-CoV-2 circulated. The protective antibody titers presented may be useful for vaccine policy and control measures. While second infections were somewhat less severe, they were not as mild as ideal. A strategy involving vaccination will be needed to ease the burden of the SARS-CoV-2 pandemic.Competing Interest StatementAubree Gordon serves on an advisory board for Janssen. All other authors report no competing interests.Funding StatementThis work was supported by the National Institute for Allergy and Infectious Diseases at the National Institute of Health [award no. R01 AI120997 to A.G., and contract no. HHSN272201400006C to A.G.], and a grant from Open Philanthropy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review boards at the Nicaraguan Ministry of Health and the University of Michigan (HUM00119145 and HUM00178355).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level data may be shared with outside investigators following University of Michigan IRB approval. Please contact Aubree Gordon (gordonal@umich.edu) to arrange for data access.